AbbVie annual net debt
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
AbbVie Net Debt Growth & History (ABBV)
AbbVie's net debt was $60.65B for fiscal 2025.
View full AbbVie company overviewAbbVie annual net debt history
| Fiscal year | Period ended | Net debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $60.65B | −$1.84B | −2.95% |
| 2024 | 2024-12-31 | $62.49B | $15.02B | +31.65% |
| 2023 | 2023-12-31 | $47.47B | −$7.52B | −13.67% |
| 2022 | 2022-12-31 | $54.99B | −$12.83B | −18.91% |
| 2021 | 2021-12-31 | $67.81B | −$10.77B | −13.70% |
| 2020 | 2020-12-31 | $78.58B | $51.42B | +189.28% |
| 2019 | 2019-12-31 | $27.16B | −$2.16B | −7.36% |
| 2018 | 2018-12-31 | $29.32B | $1.66B | +5.99% |
| 2017 | 2017-12-31 | $27.66B | −$3.70B | −11.80% |
| 2016 | 2016-12-31 | $31.36B | $8.50B | +37.17% |
| 2015 | 2015-12-31 | $22.87B | $16.66B | +268.57% |
| 2014 | 2014-12-31 | $6.20B | $1.49B | +31.58% |
| 2013 | 2013-12-31 | $4.71B | −$4.04B | −46.12% |
| 2012 | 2012-12-31 | $8.75B | — | — |
AbbVie quarterly net debt
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Net debt | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $55.91B | −$6.14B | −9.89% |
| Q1 2026 | 2026-03-31 | $55.14B | −$5.80B | −9.52% |
| Q4 2025 | 2025-12-31 | $60.65B | −$1.84B | −2.95% |
| Q3 2025 | 2025-09-30 | $61.13B | $9.88B | +19.28% |
| Q2 2025 | 2025-06-30 | $62.05B | $17.13B | +38.14% |
| Q1 2025 | 2025-03-31 | $60.95B | $15.20B | +33.24% |
| Q4 2024 | 2024-12-31 | $62.49B | $15.02B | +31.65% |
| Q3 2024 | 2024-09-30 | $51.25B | $8.91B | +21.03% |
| Q2 2024 | 2024-06-30 | $44.92B | −$2.13B | −4.54% |
| Q1 2024 | 2024-03-31 | $45.74B | −$6.84B | −13.01% |
| Q4 2023 | 2023-12-31 | $47.47B | −$7.52B | −13.67% |
| Q3 2023 | 2023-09-30 | $42.35B | −$6.23B | −12.83% |
| Q2 2023 | 2023-06-30 | $47.05B | −$5.45B | −10.37% |
| Q1 2023 | 2023-03-31 | $52.58B | −$4.85B | −8.45% |
| Q4 2022 | 2022-12-31 | $54.99B | −$12.83B | −18.91% |
| Q3 2022 | 2022-09-30 | $48.58B | −$13.31B | −21.50% |
| Q2 2022 | 2022-06-30 | $52.50B | −$13.21B | −20.10% |
| Q1 2022 | 2022-03-31 | $57.44B | −$7.00B | −10.86% |
| Q4 2021 | 2021-12-31 | $67.81B | −$10.77B | −13.70% |
| Q3 2021 | 2021-09-30 | $61.88B | −$12.56B | −16.88% |
| Q2 2021 | 2021-06-30 | $65.71B | −$10.40B | −13.66% |
| Q1 2021 | 2021-03-31 | $64.44B | $42.29B | +190.94% |
| Q4 2020 | 2020-12-31 | $78.58B | $51.42B | +189.28% |
| Q3 2020 | 2020-09-30 | $74.45B | $51.59B | +225.76% |
| Q2 2020 | 2020-06-30 | $76.11B | $48.95B | +180.28% |
| Q1 2020 | 2020-03-31 | $22.15B | −$8.94B | −28.75% |
| Q4 2019 | 2019-12-31 | $27.16B | −$2.16B | −7.36% |
| Q3 2019 | 2019-09-30 | $22.85B | −$8.62B | −27.39% |
| Q2 2019 | 2019-06-30 | $27.15B | −$3.39B | −11.10% |
| Q1 2019 | 2019-03-31 | $31.09B | $8.82B | +39.61% |
| Q4 2018 | 2018-12-31 | $29.32B | $1.66B | +5.99% |
| Q3 2018 · Sep 30 | 2018-09-30 | $31.47B | $5.15B | +19.55% |
| Q2 2018 | 2018-06-30 | $30.54B | $2.41B | +8.58% |
| Q1 2018 | 2018-03-31 | $22.27B | −$9.92B | −30.82% |
| Q4 2017 | 2017-12-31 | $27.66B | −$3.70B | −11.80% |
| Q3 2017 | 2017-09-30 | $26.33B | −$4.74B | −15.25% |
| Q2 2017 | 2017-06-30 | $28.13B | −$3.37B | −10.69% |
| Q1 2017 | 2017-03-31 | $32.19B | $9.85B | +44.11% |
| Q4 2016 | 2016-12-31 | $31.36B | $8.50B | +37.17% |
| Q3 2016 | 2016-09-30 | $31.07B | $8.17B | +35.68% |
| Q2 2016 | 2016-06-30 | $31.50B | $11.78B | +59.74% |
| Q1 2016 | 2016-03-31 | $22.33B | $18.99B | +567.48% |
| Q4 2015 | 2015-12-31 | $22.87B | $16.66B | +268.57% |
| Q3 2015 | 2015-09-30 | $22.90B | $15.85B | +224.72% |
| Q2 2015 | 2015-06-30 | $19.72B | $14.08B | +249.88% |
| Q1 2015 | 2015-03-31 | $3.35B | −$2.90B | −46.45% |
| Q4 2014 | 2014-12-31 | $6.20B | $1.49B | +31.58% |
| Q3 2014 | 2014-09-30 | $7.05B | $1.24B | +21.34% |
| Q2 2014 | 2014-06-30 | $5.63B | −$358.0M | −5.97% |
| Q1 2014 | 2014-03-31 | $6.25B | −$1.40B | −18.26% |
| Q4 2013 | 2013-12-31 | $4.71B | −$4.04B | −46.12% |
| Q3 2013 | 2013-09-30 | $5.81B | — | — |
| Q2 2013 | 2013-06-30 | $5.99B | — | — |
| Q1 2013 | 2013-03-31 | $7.64B | — | — |
| Q4 2012 | 2012-12-31 | $8.75B | — | — |
AbbVie net debt trends
Over the last five fiscal years, AbbVie's net debt decreased from $78.58B to $60.65B, a change of −$17.93B. The latest reported quarter, Q2 2026, shows $55.91B.
About the metric
What net debt means
Net debt compares a company’s interest-bearing debt with its cash and cash equivalents. Positive net debt means debt exceeds cash, while a negative value indicates the company has more cash than debt on this measure.
Calculation and source
How net debt is calculated
TickerStat calculates net debt as total interest-bearing debt minus cash and cash equivalents at the same reporting-period end. Short-term investments are not subtracted because they are not included in the standardized cash series. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review AbbVie source filings ↗Community posts
AbbVie’s menstrual-migraine study meets its primary and all ranked secondary goals
AbbVie ($ABBV) reported positive Phase 3 LUNA results for atogepant in menstrual migraine. The study enrolled 468 women and evaluated treatment across three menstrual cycles. Migraine days during the assessed menstrual period fell by 1.20 d ...